**The healthcare needs of children with Down syndrome in the first year of life: an analysis of the EUROlinkCAT data linkage study**

Sarah E Seaton\*1; Judith Rankin2; Clara Cavero-Carbonell3; Ester Garne4; Mika Gissler5; Maria Loane6; Amanda J Neville7; Michele Santoro8; Joachim Tan9; David Tucker10; Joan K Morris11

1: Department of Population Health Sciences, University of Leicester, Leicester, UK

2: Population Health Sciences Institute, Newcastle University, Newcastle, UK

3: Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, Valencia, Spain.

4: Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark

5: THL Finnish Institute for Health and Welfare, Department of Data and Analytics, Helsinki, Finland; Region Stockholm, Academic Primary Health Care Centre, Stockholm, Sweden; Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden.

6: Institute of Nursing and Health Research, Ulster University, Belfast, UK

7: IMER Registry, Centre for Clinical and Epidemiological Research University of Ferrara and Azienda Ospedaliero Universitario di Ferrara

Ferrara, Italy

8: Unit of Epidemiology of Rare diseases and Congenital anomalies, Clinical Physiology, National Council, Pisa, Italy

9: NIHR GOSH BRC, UCL Great Ormond Street Institute of Child Health, London, UK.

10: Research, Data & Digital Directorate, Public Health Wales, Swansea, UK

11: School of Health & Medical Sciences, City St George’s, University of London, London, UK.

\*Corresponding author: [sarah.seaton@leicester.ac.uk](mailto:sarah.seaton@leicester.ac.uk)

ORCID

Sarah Seaton: 0000-0001-8711-4817

Judith Rankin: 0000-0001-5355-454X

Clara Cavero-Carbonell 0000-0002-4858-6456

Ester Garne 0000-0003-0430-2594

Mika Gissler 000-0001-8254-7525

Maria Loane 0000-0002-1206-3637

Amanda J Neville Not applicable

Michele Santoro 0000-0003-0676-3036

Joachim Tan 0000-0003-0462-4761

David Tucker 0000-0003-3077-5918

Joan Morris: 0000-0002-7164-612X

**Synopsis**

**Study question**

What are the healthcare needs in the first year of life for children with Down syndrome compared to all major congenital anomalies?

**What’s already known**

Down syndrome is the most common chromosomal anomaly. There is a lack of information on specific healthcare needs of children with Down syndrome compared to children with major congenital anomalies.

**What this study adds**

Across regions of our study, >80% of children with Down syndrome had a hospital admission in the first year. Hospital length of stay was higher for children with Down syndrome compared to those with all major anomalies. Despite having similar percentages of children needing ventilation support, children with Down syndrome had higher rates of intensive care admission than all children with major anomalies.

**Abstract**

**Background**

Globally, Down syndrome is the most common chromosomal anomaly, often co-occurring with cardiac or gastrointestinal anomalies. There is a lack of robust data on specific healthcare needs of children with Down syndrome compared to children with other major congenital anomalies.

**Objectives**

To quantify the healthcare needs of children with Down syndrome in the first year of life compared to children with major congenital anomalies in a large population-based cohort across Europe.

**Methods**

The EUROlinkCAT study was a multi-centre data linkage study between congenital anomaly registries in Europe and hospital and mortality databases. Children born between 1st January 1997 to 31st December 2014 were included. Summary statistics were used to compare differences between children (those with Down syndrome compared to all major anomalies) and regions. Random-effects meta-analysis was used to pool results related to survival, need for intensive care and ventilation support.

**Results**

A total of 3,554 children were born with Down syndrome, out of 89,081 children with major congenital anomalies. The pooled one-year survival was 95.4%. In every region, >80% of children with Down syndrome had a hospital admission excluding the birth admission. Hospital length of stay in the first year was higher for children with Down syndrome compared to those with all anomalies (median: 14 versus 7 days). Despite having similar need for ventilation support (9.7% versus 8.4%), children with Down syndrome had higher rates of intensive care admission than all children with anomalies (24.8% versus 13.0%).

**Conclusions**

There is a high need for hospital care for children born with Down syndrome in the first year of life. Future work should continue to explore the long-term prognosis for children with Down syndrome to ensure their care needs are met.

**Key words:** congenital anomalies; Down syndrome; intensive care; epidemiology

**Word count:**  2769

**Background**

Congenital anomalies (conditions present at birth) are a leading cause of child mortality and morbidity globally1. Every year around 130,000 children are born in Europe with a major congenital anomaly2 and they account for around 28% of deaths in the first year of life3. Children with congenital anomalies have greater healthcare needs, for example they are known to spend 8.8 times longer in hospital in Europe over the first year of life (18 days versus two days) than children without congenital anomalies4.

As of 2015, there were an estimated 419,000 people with Down syndrome (Trisomy 21) living in Europe5. Around half of children with Down syndrome also have a cardiac anomaly and around one in 10 have gastrointestinal atresia6. For children with Down syndrome, survival to aged 10 years is highest when they do not have an associated cardiac or digestive system anomaly7. The condition is also associated with increased risk of other health conditions which may require hospital admissions, for example reduced immunity to respiratory infections8. Both the total and live birth prevalence of Down syndrome have increased over time in Europe due to increasing maternal age9.

Children with Down syndrome have higher rates of hospitalisation and readmission, and more of their admissions are emergencies compared to children without Down syndrome10. Furthermore, their hospital admission rates have increased over time10 although it is unclear if these are necessary hospital admissions. Previous work has shown that children with Down syndrome’s first admission to hospital is when they are younger, and lasts longer, than children without Down syndrome11. Of children admitted to intensive care, those with Down syndrome have a lower disease severity on admission but more of them require organ support than expected given their severity of illness12. However, much of the previous research has been from a single country or region and therefore were limited by small numbers of children.

This study aims to explore the healthcare needs of children born with Down syndrome in the first year of life, focussing on length of hospital stay, hospital admissions, surgery and intensive care and presence of additional cardiac and gastrointestinal anomalies using data collected from a large population-based cohort across Europe.

**Methods**

*Setting*

The ‘Establishing a linked European Cohort of Children with Congenital Anomalies’ (EUROlinkCAT) project was a multi-centre retrospective data-linkage cohort study. EUROlinkCAT collated data from the European Network of Congenital Anomaly Registries (EUROCAT) who were supported to link their data on children with congenital anomalies to their hospital, prescription, education, and mortality information. Not all registries that were part of EUROCAT participated in the EUROlinkCAT study. All those registries who were able to link their data on births to mortality and hospital discharges were included in this paper. The overall aim of the study was to examine mortality and morbidity outcomes of children born with congenital anomalies in the first ten years of their lives. Information on individual children was not shared with the EUROlinkCAT team, rather statistical analyses were run by each individual registry and the resulting aggregated data and analytical results on specific topics of interest were then stored in a central results repository in Ulster University2. These aggregated results were transferred to the study team to allow for the analyses in this paper. Definitions of length of stay, obstetric stay and surgery in the study have been published previously13 14.

In this study, we used the data on children born with a major congenital anomaly from 1st January 1997 to 31st December 2014, and followed up to 31st December 2015 from eight European regions: Tuscany (Italy); Emilia Romagna (Italy); Finland; Thames Valley (UK); Wessex (UK); East Midlands and South Yorkshire (EMSY, UK); Wales and Valencian Region (Spain). We focussed on outcomes and care provided in the first year of life.

Data are collected on all children with a confirmed diagnosis of a major congenital anomaly in the regions covered by EUROlinkCAT. In this paper, we focus on the subgroup of children who have a diagnosis of Down syndrome occurring with or without cardiac/gastrointestinal anomalies. Information was collated by EUROlinkCAT on children with Down syndrome’s need for hospital care, including specific procedures such as surgery, and we focus on the first year after birth.

EUROlinkCAT defines a major congenital anomaly using the definition by the World Health Organisation15, that is children living with major structural changes or chromosomal abnormalities that result in significant medical, social or cosmetic changes and typically require medical intervention e.g., spina bifida, anencephaly and orofacial clefts. Children with minor anomalies, e.g., single palmar crease and clinodactyly (curvature of the finger), were excluded from EUROlinkCAT16.

*Statistical analysis*

We compared the Kaplan-Meier one-year survival of children with Down syndrome across the different regions, obtaining an overall estimate using a random effects meta-analysis17 as we had summary data for each region. The Kaplan-Meier approach was used to account for censoring due to the study period ending 31st December 2014, meaning some children never reached their fifth birthday, although the censoring is negligible in this work as we have restricted analysis to the first year. Therefore, in this work the Kaplan-Meier estimates are similar to observed proportions. We present findings using a forest plot. We also report the observed one-year survival for children with Down syndrome and/or congenital heart disease (CHD) and/or gastrointestinal anomalies. The group of “all children with a major congenital anomaly” includes those with Down syndrome.

We compared selected clinical needs of all children with a major congenital anomaly to only those children with Down syndrome using summary statistics (total and percentages estimated using Kaplan Meier to account for censoring). We compared the percentage of children that were admitted to hospital in the first year of life; need for surgery and their length of stay in hospital outside of the birth admission. The total percentages are estimated from a random-effects meta-analysis to allow for variation between countries.

To estimate pooled estimates of median length of stay we used quantile estimation methods.18 These methods use the reported median and quartiles for each registry to select an underlying parametric distribution based on the best-fit of normal, log-normal, gamma and Weibull distributions. The asymptotic variance of the median can then be calculated, and a random effects meta-analysis performed19. We considered this for all anomalies; Down syndrome and Down syndrome with/without the additional presence of CHD.

Data on intensive care and ventilation were available for a smaller subset of data due to changes in data collection procedures over time in the hospital databases. All analysis for these outcomes were therefore performed on subsets of data during which these outcomes were reported. We considered the percentage of children (by all anomalies and those with Down syndrome) who required admission to intensive care or required ventilation support, again pooling overall estimates using a random effects meta-analysis and presenting using forest plots.

*Missing data*

We were unable to impute for missing data as we did not have individual level data and when the data were missing (e.g., for intensive care data) this was at a registry level and therefore systematically missing.

*Ethics approval*

All registries obtained ethical and other permissions for the data linkage according to their national legislations. Ulster University obtained ethics permission for the Central Results Repository which hosts the EUROlinkCAT Central Repository on 15th September 2017 (Institute of Nursing and Health Research Ethics Filter Committee, number FCNUR-­17-­000).

**Results**

We obtained aggregated data related to 89,081 liveborn children with congenital anomalies born from 1st January 1997 to 31st December 2014 across eight European regions covering a birth population of over 3.6 million. The largest population of children were from Finland (n=38,324, Table 1). In total, 3,554 (4.0%) children with a diagnosis of a congenital anomaly had Down syndrome.

For children with Down syndrome, survival at one year was high across all European regions, ranging from 92.7% (EMSY) to 97.3% (Emilia Romagna) (Figure 1). We obtained a pooled estimate of overall survival of 95.4% (95% CI 94.3, 96.5) across all regions (Figure 1). Survival was lower for children with associated anomalies, for example in children with CHD and a gastrointestinal anomaly pooled survival was 88.9% (95% CI 84.2, 93.6) (Appendix 1).

*Hospitalisation and length of stay*

For children with all anomalies, the percentage of children admitted to hospital (outside of the birth admission), ranged from 60.7% (Finland) to 96.5% (Valencian Region) (Table 1). However, this was higher for children with Down syndrome, with all regions reporting hospital admission percentages of over 80% (Table 1).

Children with Down syndrome had longer hospital length of stay in the first year of life (Table 2) than children with all anomalies across all regions (Table 2). The median lengths of stay varied from three days longer (Wessex) to 12 days longer (Tuscany and Finland). There were also notable regional differences between children with Down syndrome and CHD having longer stays than those children with Down syndrome without CHD. The total median length of stay in the first year for these children ranged from 15 days (Wales) to 33 days (Tuscany) (Table 2).

Overall, a slightly higher percentage of children with all anomalies underwent surgery than children with Down syndrome (pooled estimate: 38.3% versus 33.4%, Table 3). However, there were more marked differences in individual regions; for example, in Wessex, 48.9% of children with all anomalies required surgery compared to 31.4% with Down syndrome.

*Need for more advanced care*

Finally, we considered the children’s need for admission to intensive care and need for ventilation in the first year of life. The number of children included in the intensive care analysis was 29,383 (all anomalies) and 995 (Down syndrome) and in the ventilation analysis it was 41,507 (all anomalies) and 1,752 (Down syndrome). In this subset of children, we observed that the overall need for admission to intensive care was much higher amongst those children with Down syndrome versus those with all anomalies (25% versus 13%, Figure 2) and this was true across all regions. Both groups of children had similar levels of needing ventilation (9% versus 10%, Figure 2) overall although this varied by region, e.g., in Tuscany this was 14% of children with all anomalies and 26% of children with Down syndrome.

**Comment**

*Principal findings*

Our study examined the healthcare needs of 3,554 children living with Down syndrome over the first year of life across eight European regions. Survival for these children in the first year was 95.4% overall, and consistently above 93% across all regions. We identified high levels of hospital admissions outside of the birth admission, and need for surgery varied across regions. Whilst we have limited data, our findings suggest that children with Down syndrome were potentially admitted to intensive care units with less severe illness, indicated by higher admission rates but similar levels of ventilation need compared to children with all anomalies.

*Strengths of the study*

The major strength of our study is the population-based approach which does not rely on records from individual hospitals which can result in biases. Pooling standardised data from multiple registries across several European countries allows for more accurate quantification of risks of specific outcomes for children living with Down syndrome. The included registries provide standardised data from high quality population-based registers who are all members of EUROCAT and follow a consistent approach to coding. Each register includes cases of congenital anomalies occurring in livebirths, stillbirths, termination of pregnancy for fetal anomaly and late miscarriage. This study relied on successful linkage of children with their healthcare data which has been shown in previous EUROlinkCAT studies to be high (>95%) and similar for children with congenital anomalies and those without in the wider project4. Pooling data from a number of registries across several European regions has enabled the association of additional anomalies with Down syndrome to be explored.

*Limitations of the data*

We were unable to undertake any analysis on an individual level and were restricted to the analyses we were able to perform on aggregated data. We were unable to account for any potential confounders (e.g., preterm birth) due to not having child-level data. However, a strength of our work is that we used appropriate statistical approaches, including random effects meta-analysis, to pool results. We could not compare children with Down syndrome to a group that did not include Down syndrome, as the primary aim of EUROlinkCAT was to describe outcomes for children with specific congenital anomalies as a whole (comprising children with isolated anomalies as well as those with associated anomalies). However, because Down syndrome made up a small percentage of all congenital anomalies, the comparison is approximately that of two distinct groups (children with Down syndrome make up ~4% of the overall congenital anomaly group). We also had a substantially reduced sample size when considering need for intensive care and ventilation as data on these outcomes were only available for a restricted number of years for several registries due to changes in local data collection procedures over time. We could not consider the co-existence of other anomalies and we were unable to explore the reasons for the need for intensive care admission or need for ventilation. This could relate to their heart condition (for those who have them) or being at increased risk of other complications such as respiratory conditions.

*Interpretation*

Whilst overall survival was around 95%, this was lower when considering children with additional structural anomalies. For those children who also had CHD and a gastrointestinal anomaly survival was 89%. Other research has shown that the probability of survival is substantially lower in children with Down syndrome and CHD compared to matched controls from the general population and compared to children with only CHD20. This demonstrates the added complexity of living with multiple lifelong health conditions as a child and into adulthood, the numbers of which have been increasing over time21.

In all children with Down syndrome, we observed an overall hospital admission rate of 88%, similar to that seen in previous research from Scotland which observed a hospitalisation rate of >90% which had increased slightly over time 10. The high hospitalisation rate we observed was lower for those children with Down syndrome without CHD, but it still remained above 80%, consistently higher than for all children with congenital anomalies.

The median length of stay in hospital in the first year of life was consistently higher for children with Down syndrome compared to those children with all anomalies across all regions. The median total length of hospital stay ranged from three days longer (Wessex) to 12 days (Finland and Tuscany). This is similar to other research which has shown that children with Down syndrome are admitted at a younger age and have longer inpatient stays than children without Down syndrome11. We were able to compare children with Down syndrome with CHD and those without CHD and this demonstrated that much longer lengths of stay were seen in children with Down syndrome and CHD (23 days versus nine days).

Variation in surgery across regions may have resulted from variations in termination rates due to differences in prenatal screening practice. For example, first trimester ultrasound screening is more likely to pick up fetuses with CHD which may lead to a termination of the pregnancy. Therefore, if such screening occurs the proportion of livebirths with CHD may be lower than in regions without this screening.

Our finding that children with Down syndrome were potentially admitted to intensive care units with less severe illness may reflect a cautious approach to their care such as following surgery where other children might be cared for in lower-level environments, children with Down syndrome may be admitted to intensive care. This reflects previous work where children with Down syndrome had potentially higher than expected organ support given their disease severity12. This is important for families and healthcare professionals to explore further as admission to intensive care is not without risks including being traumatic for families22 23 when other settings may have been as or more appropriate to provide care. However, these findings should be interpreted with caution as data quality is likely to be poorer for these variables and collection may vary across regions. We also do not know the reasons for the child’s admission to intensive care.

*Conclusions*

There is a high need for hospital care for children born with Down syndrome in the first year of life, but we found indications that this care may not always be in the most appropriate location. It is important that information about the care pathway from antenatal diagnosis to one year of age is shared with families. Future work should continue to explore the long-term prognosis for children with Down syndrome to ensure their care needs are met.

**References**

1 Boyle B, Addor M, Arriola L, Barisic I, Bianchi F, Csáky-Szunyogh M, de Walle HEK, Dias CM, Draper E, Gatt M, Garne E, Haeusler M, Källén K, Latos-Bielenska A, McDonnell B, Mullaney C, Nelen V, Neville AJ, O’Mahony M, Queisser-Wahrendorf A, Randrianaivo H, Rankin J, Rissmann A, Ritvanen A, Rounding C, Tucker D, Verellen-Dumoulin C, Wellesley D, Wreyford B, Zymak-Zakutnia N, Dolk H. Estimating Global Burden of Disease due to congenital anomaly: an analysis of European data*. Archives of disease in childhood. Fetal and neonatal edition* 2018; 103:F22–F28.

2 Morris JK, Garne E, Loane M, Barisic I, Densem J, Latos-Bieleńska A, Neville A, Pierini A, Rankin J, Rissmann A, de Walle H, Tan J, Given JE, Claridge H. EUROlinkCAT protocol for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies*. BMJ open* 2021; 11:e047859.

3 Pitt MJ, Morris JK. European trends in mortality in children with congenital anomalies: 2000–2015*. Birth Defects Research* 2021; 113:958–967.

4 Morris JK, Loane M, Wahlich C, Tan J, Baldacci S, Ballardini E, Cavero-Carbonell C, Damkjær M, García-Villodre L, Gissler M, Given J, Gorini F, Heino A, Limb E, Lutke R, Neville A, Rissmann A, Scanlon l, Tucker DF, Urhoj SK, de Walle HE, Garne E. Hospital care in the first 10 years of life of children with congenital anomalies in six European countries: data from the EUROlinkCAT cohort linkage study*. Archives of disease in childhood* 2024; 109:402–408.

5 de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Europe*. European journal of human genetics : EJHG* 2021; 29:402–410.

6 Bunt CW, MD, Bunt SK, PhD. Role of the Family Physician in the Care of Children with Down Syndrome*. American family physician* 2014; 90:851–858.

7 Glinianaia SV, Rankin J, Pierini A, Coi A, Santoro M, Tan J, Reid A, Garne E, Loane M, Given J, Cavero-Carbonell C, de Walle HEK, Gatt M, Gissler M, Heino A, Khoshnood B, Klungsøyr K, Lelong N, Neville AJ, Thayer DS, Tucker D, Urhøj SK, Wellesley D, Zurriaga O, Morris JK. Ten-Year Survival of Children With Congenital Anomalies: A European Cohort Study*. Pediatrics (Evanston)* 2022; 149:13.

8 Prayle A, Vyas H. Respiratory problems in children with Down syndrome*. Paediatrics and child health* 2021; 31:271–275.

9 Loane M, Morris JK, Addor M, Arriola L, Budd J, Doray B, Garne E, Gatt M, Haeusler M, Khoshnood B, Klungsøyr Melve K, Latos-Bielenska A, McDonnell B, Mullaney C, O'Mahony M, Queisser-Wahrendorf A, Rankin J, Rissmann A, Rounding C, Salvador J, Tucker D, Wellesley D, Yevtushok L, Dolk H. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening*. European Journal of Human Genetics* 2013; 21:27–33.

10 Hughes-McCormack LA, McGowan R, Pell JP, Mackay D, Henderson A, O'Leary L, Cooper S. Birth incidence, deaths and hospitalisations of children and young people with Down syndrome, 1990–2015: birth cohort study*. BMJ open* 2020; 10:e033770.

11 Esperanza RA, Evans A, Tucker D, Paranjothy S, Hurt L. Hospital admissions in infants with Down syndrome: a record‐linked population‐based cohort study in Wales*. Journal of intellectual disability research* 2022; 66:225–239.

12 Tibby SM, Durward A, Goh CT, Thorburn K, Morris K, Broadhead M, Peters MJ. Clinical course and outcome for critically ill children with Down syndrome: a retrospective cohort study*. Intensive care medicine* 2012; 38:1365–1371.

13 Urhoj SK, Tan J, Morris JK, Given J, Astolfi G, Baldacci S, Barisic I, Brigden J, Cavero-Carbonell C, Evans H, Gissler M, Heino A, Jordan S, Lutke R, Odak L, Puccini A, Santoro M, Scanlon I, de Walle HEK, Wellesley D, Zurriaga Ó, Loane M, Garne E. Hospital length of stay among children with and without congenital anomalies across 11 European regions—A population-based data linkage study*. PloS one* 2022; 17:e0269874.

14 Garne E, Loane M, Tan J, Ballardini E, Brigden J, Cavero‐Carbonell C, Coi A, Damkjær M, Garcia‐Villodre L, Gissler M, Given J, Heino A, Jordan S, Limb E, Neville A, Rissmann A, Santoro M, Scanlon I, Urhoj SK, Wellesley D, Morris J. European study showed that children with congenital anomalies often underwent multiple surgical procedures at different ages across Europe*. Acta Paediatrica* 2023; 112:1304–1311.

15 Anonymous . World Health Organisation. Congenital Disorders. Online at: <https://www.who.int/news-room/fact-sheets/detail/birth-defects> [last accessed: 13/8/2024].

16 Anonymous . EUROCAT Guide. 1.4 Minor anomalies and other conditions for exclusion. Online at: <https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/JRC-EUROCAT-Section-3.2-23-9-2020.pdf> [last accessed: 8/10/2024].

17 DerSimonian R, Laird N. Meta-analysis in clinical trials revisited*. Contemporary clinical trials* 2015; 45:139–145.

18 McGrath S, Sohn H, Steele R, Benedetti A. Meta‐analysis of the difference of medians*. Biometrical journal* 2020; 62:69–98.

19 Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis*. Research Synthesis Methods* 2010; 1:97–111.

20 Engsner S, Giang KW, Dellborg M, Fedchenko M, Eriksson P, Mandalenakis Z. Impact of Down Syndrome on Survival Among Patients With Congenital Heart Disease*. Journal of the American Heart Association* 2024; 13:e031392.

21 Jarvis S, Richardson G, Flemming K, Fraser LK. Numbers, characteristics, and medical complexity of children with life-limiting conditions reaching age of transition to adult care in England: a repeated cross-sectional study*. NIHR open research* 2022; 2:27.

22 Colville G, Pierce C. Patterns of post-traumatic stress symptoms in families after paediatric intensive care*. Intensive care medicine* 2012; 38:1523–1531.

23 Nelson LP, Gold JI. Posttraumatic stress disorder in children and their parents following admission to the pediatric intensive care unit: a review*. Pediatric critical care medicine* 2012; 13:338–347.

**Acknowledgements:** For the purpose of open access, the author has applied a Creative Commons Attribution license (CC BY) to any Author Accepted Manuscript version arising from this submission.

We are very grateful to the whole EUROlinkCAT Working Group for their contribution to the project (data linkage and standardisation, running syntax scripts): Dr Joanne Given (Ulster University, Belfast, United Kingdom); Drs L. Renée Lutke and Nicole Siemensma-Mühlenberg (University Medical Centre Groningen, Groningen, The Netherlands); Dr Oscar Zurriaga, Sandra Moreno Marro, Laia Barrachina Bonet and Laura García Villodre (Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, Valencia, Spain); Dr Sonja Kiuru-Kuhlefelt, Anna Heino and Tuuli Puroharju (THL Finnish Institute for Health and Welfare. Helsinki, Finland); Drs Alessio Coi and Michele Santoro (Institute of Clinical Physiology, National Research Council, Pisa, Italy); Drs Gianni Astolfi, Aurora Puccini, Annarita Armaroli (Center for Clinical and Epidemiological Research, University of Ferrara, Ferrara, Italy); Nathalie Bertille and Dr Babak Khoshnood (INSERM, Paris, France); Professor Sue Jordan (Swansea University, Swansea, Wales, UK); Professor Elizabeth Draper (University of Leicester, Leicester, UK) and Professor Jenny Kurinczuk (University of Oxford, Oxford, UK). We would also like to thank Mr Hugh Claridge (Population Health Research Institute, St George’s, University of London, London, UK) for project management.

**Data availability:** The data in the EUROlinkCAT project are sensitive as they relate to children with congenital anomalies, many of which are rare. The study team had access to aggregate data only from each region i.e., the linked patient level data remained in the local region. We will make all our documentation available and encourage any interested parties to apply to the EUROlinkCAT management team to assist them in obtaining approval from the data providers in each region/country to use the aggregated data for an approved study.

**Funding statement:** Sarah Seaton (Advanced Fellowship: NIHR300579) is funded by the National Institute for Health and Care Research for this research project. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.

**Conflicts of interest:** The authors have no conflicts of interest to declare.

**Contributions:** JM, JR, ML, DT obtained funding for the original EUROlinkCAT project.SS completed the analysis under the supervision of JR and JM. SS wrote the first draft of the paper. All authors revised the paper providing critique and intellectual contribution.

**Ethics:** All registries obtained ethical and other permissions for the data linkage according to their national legislations. The University of Ulster obtained ethics permission for the Central Results Repository on 15 September 2017 (Institute of Nursing and Health Research Ethics Filter Committee, number FCNUR-­17-­000).

**Table 1: Number of children age <1 year by anomaly status, outcome and by admission to hospital**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Birth population covered (1,000s)a** | **All children with a major congenital anomaly (including Down syndrome)** | | **All children with Down syndrome** | | **Children with Down syndrome and CHD present** | | **Children with Down syndrome and no CHD** | |
| **Registry**  **(Years)** |  | **Hospital admission (Total births)** | **%, (95% CI)b** | **Hospital admission (Total births)** | **%, (95% CI)b** | **Hospital admission (Total births)** | **%, (95% CI)b** | **Hospital admission (Total births)** | **%, (95% CI)b** |
| Tuscany, Italy  2005-2014 | 300 | 3938  (4225) | 93.2,  (92.4, 94.0) | 143  (148) | 96.6,  (92.8, 98.7) | 52  (54) | 96.3,  (88.7, 99.3) | 91  (94) | 96.8,  (91.7, 99.1) |
| Emilia Romagna, Italy  2008-2014 | 282 | 5051  (5381) | 93.9,  (93.2, 94.5) | 202  (206) | 98.1,  (95.4, 99.4) | 78  (79) | 98.7,  (93.9, 99.9) | 124  (127) | 97.6,  (93.8, 99.4) |
| Finland  1997-2014 | 953 | 23156  (38324) | 60.7,  (60.3, 61.2) | 1001  (1205) | 83.4,  (81.2, 85.4) | 649  (722) | 90.2,  (87.9, 92.2) | 352  (483) | 73.2,  (69.2, 77.1) |
| Wales  1998-2014 | 559 | 12429  (17448) | 71.9  (71.3, 72.6) | 460  (562) | 82.1,  (78.9, 85.2) | 302  (349) | 86.6,  (82.8, 89.9) | 158  (213) | 74.8  (68.8, 80.5) |
| Thames Valley, UK  2005-2013 | 270 | 3452  (3845) | 92.1,  (91.2, 93.0) | 237  (262) | 92.9,  (89.0, 95.8) | 79  (80) | 100.0c | 158  (182) | 89.2,  (83.8, 93.5) |
| Wessex, UK  2004-2014 | 325 | 3797  (4320) | 89.5,  (88.5, 90.4) | 304  (334) | 92.7,  (89.4, 95.3) | 85  (91) | 95.7,  (89.4, 98.8) | 219  (243) | 91.6,  (87.5, 94.8) |
| EMSY, UK  2003-2012 | 717 | 10116  (11278) | 91.8,  (91.2, 92.3) | 633  (682) | 94.2,  (90.6, 94.6) | 233  (243) | 98.3,  (95.5, 99.5) | 400  (439) | 92.3,  (89.4, 94.6) |
| Valencian Region, Spain  2010-2014 | 228 | 4112  (4260) | 96.5,  (96.0, 97.0) | 152  (155) | 98.1,  (94.9, 99.5) | 101  (101) | 100.0c | 51  (54) | 94.4,  (86.1, 98.5) |
| **Total** | 3634 | 66051  (89081) | 86.2,  (75.6, 96.7) | 3132  (3554) | 92.3,  (87.9, 96.6) | 1579  (1719) | 94.3,  (90.1, 98.4) | 1553  (1835) | 88.9  (82.8, 94.9) |

**a** Extracted from the EUROCAT website (https://eu-rd-platform.jrc.ec.europa.eu/ eurocat/eurocat-data/prevalence\_en), accessed on 30 September 2021.

b Kaplan Meier estimates to account for censoring

c not calculated and excluded from pooled estimate

CHD: congenital heart disease; UK: United Kingdom; CI: confidence interval; EMSY: East Midlands and South Yorkshire

**Table 2**: Length of hospital stay in first year of life (excluding initial birth admission) (days)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Length of stay in hospital for children with all anomalies, median (25th, 75th)** | **Length of stay in hospital for children with Down syndrome, median (25th, 75th)** | **Length of stay in hospital for children with Down syndrome and CHD present, median (25th, 75th)** | **Length of stay in hospital for children with Down syndrome and no CHD, median (25th, 75th)** |
| Tuscany, Italy | 7 (3, 21) | 19 (7, 43) | 33 (16, 79) | 11 (6, 22) |
| Emilia Romagna, Italy | 8 (3, 21) | 14 (5, 31) | 31 (17, 54) | 7 (4, 18) |
| Finland | 7 (3, 21) | 19 (8, 41) | 23 (11, 50) | 12 (4, 26) |
| Wales | 6 (2, 18) | 11 (3, 28) | 15 (5, 36) | 6 (2, 16) |
| Thames Valley, UK | 7 (3, 21) | 12 (5, 24) | 21 (10, 39) | 9 (4, 19) |
| Wessex, UK | 9 (3, 25) | 12 (6, 26) | 24 (13, 45) | 9 (4, 21) |
| East Midlands & South Yorkshire, UK | 7 (3, 25) | 15 (6, 35) | 31 (17, 62) | 9 (4, 21) |
| Valencian Region, Spain | 9 (3, 23) | 17 (7, 31) | 18 (8, 32) | 15 (5, 29) |
| Overall median and 95% CI of median\* | 7 (7, 8) | 14 (12, 17) | 23 (19, 28) | 9 (8, 11) |

CHD: congenital heart disease; UK: United Kingdom

**Table 3:** Number of children who underwent surgery in the first year of life for those with Down syndrome and all anomalies

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Registry** | **Children with all anomalies requiring surgery** | | | **Children with Down Syndrome requiring surgery** | | |
|  | **Total children with all anomalies** | **Total children needing surgery** | **% (95% CI)** | **Total children with Down syndrome** | **Total children with Down syndrome needing surgery** | **% (95%CI)** |
| Tuscany, Italy | 4225 | 1315 | 31.1  (29.7, 32.5) | 148 | 53 | 35.8  (28.1, 44.1) |
| Emilia Romagna, Italy | 5381 | 1998 | 37.1  (35.8, 38.4) | 206 | 62 | 30.1  (23.9, 36.7) |
| Finland | 38324 | 10391 | 27.1  (26.7, 27.6) | 1205 | 421 | 34.9  (32.2, 37.8) |
| Wales | 17448 | 7417 | 42.5  (41.8, 43.2) | 562 | 246 | 43.8  (39.7, 48.0) |
| Thames Valley, UK | 3845 | 1741 | 45.3  (43.7, 46.9) | 262 | 67 | 25.6  (20.4, 31.3) |
| Wessex, UK | 4320 | 2111 | 48.9  (47.3, 50.4) | 334 | 105 | 31.4  (26.5, 36.7) |
| EMSY, UK | 11278 | 4745 | 42.1  (41.1, 43.0) | 682 | 245 | 35.9  (32.3, 39.7) |
| Valencian Region, Spain | 4260 | 1365 | 32.0  (30.6, 33.5) | 155 | 43 | 27.7  (20.9, 35.5) |
| **Total** | 89081 | 31083 | 38.3  (32.0, 44.5) | 3554 | 1242 | 33.4  (29.6, 37.3) |

EMSY: East Midlands and South Yorkshire

**Figure 1**: One year survival of children with Down syndrome



**Figure 2:** Need for admission to intensive care or required ventilation in the first year of life



**Appendix 1:** Overall one-year survival of children with Down syndrome and other associated anomalies

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Tuscany, Italy | Emilia Romagna, Italy | Finland | Wales | Thames Valley, UK | Wessex, UK | EMSY, UK | Valencian Region, Spain | Overall |
|  | %  (95% CI) | %  (95% CI) | %  (95% CI) | %  (95% CI) | %  (95% CI) | %  (95% CI) | %  (95% CI) | %  (95% CI) | Pooled %  (95% CI) |
| All Down syndrome | 95.5  (90.7, 97.8) | 97.3  (94.0, 98.8) | 95.6  (94.3, 96.5) | 93.7  (91.4, 95.4) | 97.2  (94.3, 98.7) | 96.3  (93.6, 97.9) | 92.7  (90.4, 94.4) | 95.5  (92.2, 97.4) | 95.4  (94.3, 96.5) |
| Down syndrome with CHD and gastrointestinal | -\* | -\* | 90.9  (83.3, 95.2) | 85.0  (69.6, 92.7) | 92.3  (56.6, 98.9) | 92.3  (56.6, 98.9) | 80.0  (56.6, 98.9) | 81.8  (44.7, 95.1) | 88.9  (84.2, 93.6) |
| Down syndrome with CHD and no gastrointestinal | 90.2  (78.0, 95.8) | 92.5  (84.1, 96.6) | 95.2  (93.4, 96.6) | 93.7  (90.5, 95.9) | 98.4  (89.3, 99.8) | 93.1  (84.1, 97.0) | 89.6  (84.6, 93.0) | 95.5  (90.8, 97.8) | 94.1  (92.5, 95.8) |
| Down syndrome with gastrointestinal and no CHD | 88.9  (43.3, 98.4) | -\* | 96.1  (85.2, 99.0) | 94.1  (65.0, 99.1) | -\* | -\* | 95.7  (72.9, 99.4) | -\* | 95.5  (89.9, 100.0) |
| Down syndrome with no CHD and no gastrointestinal | 98.9  (92.4, 99.8) | -\* | 97.0  (95.0, 98.2) | 95.2  (91.2, 97.4) | 97.1  (93.2, 98.8) | 97.3  (94.2, 98.8) | 94.9  (92.2, 96.6) | 96.8  (90.5, 99.0) | 96.6  (90.5, 99.0) |

\*Due to too few births, not estimated and excluded from pooled estimates

CHD: congenital heart disease; EMSY: East Midlands and South Yorkshire; UK: United Kingdom